Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022
Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)
DOI: 10.6004/jnccn.2026.7043 ↗Abstract
Background: Nearly half of patients with advanced non–small cell lung cancer (aNSCLC) have actionable mutations that can be detected through broad-based genomic sequencing (BGS) or focused biomarker testing (FBT). Although national guidelines advocate for early BGS, its impact on survival in the era of targeted therapy remains unclear. This study evaluates whether BGS is associated with improved progression-free survival (PFS) and overall survival (OS) compared with FBT. Patients and Methods: This retrospective cohort study used electronic health record data from the Flatiron Health Research Database (2016–2022), which includes data from approximately 280 US academic and community oncology clinics. Adults (age ≥18 years) with stage IIIB–IV NSCLC who received at least one line of systemic therapy were included. Patients were categorized based on receipt of BGS or FBT
EUVIMED